texas oncology more breakthroughs. more victories
Some of our cancer centers may have important notifications found on the location page. View More Important Notifications x
Request an Appointment

Fort Worth Clinical Trials

Texas Oncology cancer centers in Fort Worth participate in a wide range of clinical trials and ground-breaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the Fort Worth area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the Fort Worth area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks of Participating in Clinical Trials

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the Fort Worth area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the Fort Worth area and talk to you doctor to determine which clinical trial is right for you.

Anal Cancer

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Grapevine

Phase: III

Biliary Cancer

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: II

Breast Cancer

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant InvestigatorÂ's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 DAto-DXd PD1/PD L1 BC (TROPION Breast02) View

Description: D926PC00001: A Phase III Open-label Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02).

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Imlun vs Endo ER+ HER2- BC View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Carcinoid

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Bedford

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Grapevine

Phase: II

Cervical Cancer

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Colon Cancer

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Grapevine

Phase: III

Endometrial Cancer

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Esophageal Cancer

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Fallopian Tube Cancer

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph1b TRK-950 Ovarian Peri & Fallopian View

Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 XMT-1536 in Combo HGSOC (UPGRADE-A) View

Description: STUDY MER-XMT-1536-2A: UPIFITAMAB RILSODOTIN (XMT-1536) AN OPEN-LABEL MULTICENTER DOSE ESCALATION AND EXPANSION STUDY OF UPIFITAMAB RILSODOTIN IN COMBINATION WITH CARBOPLATIN IN PARTICIPANTS WITH HIGH-GRADE SEROUS OVARIAN CANCER(UPGRADE-A)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 EpiOvarian FallTube PriPeritoneal View

Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 EpiOvarian FallTube PriPeritoneal View

Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Gastric Cancer

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Head and Neck Cancer

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington South

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: I

Hematologic

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Leukemia

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Lung Cancer

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph II/III Raptor trial View

Description: Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial (NRG-LU007)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II/III

Title: PH2 MORab-202 NSCLC View

Description: A Phase 2 Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin) a Folate Receptor Alpha-targeting Antibody-Drug Conjugate in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: PH2 MORab-202 NSCLC View

Description: A Phase 2 Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin) a Folate Receptor Alpha-targeting Antibody-Drug Conjugate in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: PH2 MORab-202 NSCLC View

Description: A Phase 2 Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin) a Folate Receptor Alpha-targeting Antibody-Drug Conjugate in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: PH2 MORab-202 NSCLC View

Description: A Phase 2 Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin) a Folate Receptor Alpha-targeting Antibody-Drug Conjugate in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Lymphomas

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: PH3 R-CHOP +/- Acalab Tx Naive DLBCL View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects < or = 70 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma (ACE-LY-312/ D8227C00001)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Melanoma

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Myelomas

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Ovarian Cancer

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph1b/2 XMT-1536 ST NaPi2b View

Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph1b/2 XMT-1536 ST NaPi2b View

Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1b TRK-950 Ovarian Peri & Fallopian View

Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 XMT-1536 in Combo HGSOC (UPGRADE-A) View

Description: STUDY MER-XMT-1536-2A: UPIFITAMAB RILSODOTIN (XMT-1536) AN OPEN-LABEL MULTICENTER DOSE ESCALATION AND EXPANSION STUDY OF UPIFITAMAB RILSODOTIN IN COMBINATION WITH CARBOPLATIN IN PARTICIPANTS WITH HIGH-GRADE SEROUS OVARIAN CANCER(UPGRADE-A)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 EpiOvarian FallTube PriPeritoneal View

Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 EpiOvarian FallTube PriPeritoneal View

Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Pancreatic Cancer

Title: A Phase I/II randomized, double-blind, placebo-controlled trial(1-BETTER) examining XB2001 (anti-IL-1? True Humanantibody) in combination with ONIVYDE + 5-FU/LV(+folinic acid) in advanced pancreatic cancer

Indication: Pancreatic Cancer

Location: Texas Oncology-Arlington South

Title: A Phase I/II randomized, double-blind, placebo-controlled trial(1-BETTER) examining XB2001 (anti-IL-1? True Humanantibody) in combination with ONIVYDE + 5-FU/LV(+folinic acid) in advanced pancreatic cancer

Indication: Pancreatic Cancer

Location: Texas Oncology-Arlington Cancer Center North

Peritoneal Cancer

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph1b TRK-950 Ovarian Peri & Fallopian View

Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 XMT-1536 in Combo HGSOC (UPGRADE-A) View

Description: STUDY MER-XMT-1536-2A: UPIFITAMAB RILSODOTIN (XMT-1536) AN OPEN-LABEL MULTICENTER DOSE ESCALATION AND EXPANSION STUDY OF UPIFITAMAB RILSODOTIN IN COMBINATION WITH CARBOPLATIN IN PARTICIPANTS WITH HIGH-GRADE SEROUS OVARIAN CANCER(UPGRADE-A)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 EpiOvarian FallTube PriPeritoneal View

Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 EpiOvarian FallTube PriPeritoneal View

Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Prostate Cancer

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Solid Tumors

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Uterine Cancer

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Texas Oncology-Arlington Cancer Center North

Title: A Phase I/II randomized, double-blind, placebo-controlled trial(1-BETTER) examining XB2001 (anti-IL-1? True Humanantibody) in combination with ONIVYDE + 5-FU/LV(+folinic acid) in advanced pancreatic cancer

Indication: Pancreatic Cancer

Location: Texas Oncology-Arlington Cancer Center North

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: PH2 MORab-202 NSCLC View

Description: A Phase 2 Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin) a Folate Receptor Alpha-targeting Antibody-Drug Conjugate in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Texas Oncology-Arlington South

Title: A Phase I/II randomized, double-blind, placebo-controlled trial(1-BETTER) examining XB2001 (anti-IL-1? True Humanantibody) in combination with ONIVYDE + 5-FU/LV(+folinic acid) in advanced pancreatic cancer

Indication: Pancreatic Cancer

Location: Texas Oncology-Arlington South

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington South

Phase: I

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: PH2 MORab-202 NSCLC View

Description: A Phase 2 Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin) a Folate Receptor Alpha-targeting Antibody-Drug Conjugate in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: I/II

Texas Oncology-Bedford

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Bedford

Phase: III

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Bedford

Phase: II

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 EpiOvarian FallTube PriPeritoneal View

Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: I

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: II

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PH2 MORab-202 NSCLC View

Description: A Phase 2 Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin) a Folate Receptor Alpha-targeting Antibody-Drug Conjugate in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph1b/2 XMT-1536 ST NaPi2b View

Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 EpiOvarian FallTube PriPeritoneal View

Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 EpiOvarian FallTube PriPeritoneal View

Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Texas Oncology-Fort Worth Cancer Center

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant InvestigatorÂ's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 DAto-DXd PD1/PD L1 BC (TROPION Breast02) View

Description: D926PC00001: A Phase III Open-label Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02).

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Imlun vs Endo ER+ HER2- BC View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1b TRK-950 Ovarian Peri & Fallopian View

Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 XMT-1536 in Combo HGSOC (UPGRADE-A) View

Description: STUDY MER-XMT-1536-2A: UPIFITAMAB RILSODOTIN (XMT-1536) AN OPEN-LABEL MULTICENTER DOSE ESCALATION AND EXPANSION STUDY OF UPIFITAMAB RILSODOTIN IN COMBINATION WITH CARBOPLATIN IN PARTICIPANTS WITH HIGH-GRADE SEROUS OVARIAN CANCER(UPGRADE-A)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 EpiOvarian FallTube PriPeritoneal View

Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph II/III Raptor trial View

Description: Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial (NRG-LU007)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II/III

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH3 R-CHOP +/- Acalab Tx Naive DLBCL View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects < or = 70 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma (ACE-LY-312/ D8227C00001)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1b/2 XMT-1536 ST NaPi2b View

Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1b TRK-950 Ovarian Peri & Fallopian View

Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 XMT-1536 in Combo HGSOC (UPGRADE-A) View

Description: STUDY MER-XMT-1536-2A: UPIFITAMAB RILSODOTIN (XMT-1536) AN OPEN-LABEL MULTICENTER DOSE ESCALATION AND EXPANSION STUDY OF UPIFITAMAB RILSODOTIN IN COMBINATION WITH CARBOPLATIN IN PARTICIPANTS WITH HIGH-GRADE SEROUS OVARIAN CANCER(UPGRADE-A)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 EpiOvarian FallTube PriPeritoneal View

Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1b TRK-950 Ovarian Peri & Fallopian View

Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 XMT-1536 in Combo HGSOC (UPGRADE-A) View

Description: STUDY MER-XMT-1536-2A: UPIFITAMAB RILSODOTIN (XMT-1536) AN OPEN-LABEL MULTICENTER DOSE ESCALATION AND EXPANSION STUDY OF UPIFITAMAB RILSODOTIN IN COMBINATION WITH CARBOPLATIN IN PARTICIPANTS WITH HIGH-GRADE SEROUS OVARIAN CANCER(UPGRADE-A)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 EpiOvarian FallTube PriPeritoneal View

Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Texas Oncology-Grapevine

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: I

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: PH2 MORab-202 NSCLC View

Description: A Phase 2 Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin) a Folate Receptor Alpha-targeting Antibody-Drug Conjugate in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

No Phase

Title: A Phase I/II randomized, double-blind, placebo-controlled trial(1-BETTER) examining XB2001 (anti-IL-1? True Humanantibody) in combination with ONIVYDE + 5-FU/LV(+folinic acid) in advanced pancreatic cancer

Indication: Pancreatic Cancer

Location: Texas Oncology-Arlington South

Title: A Phase I/II randomized, double-blind, placebo-controlled trial(1-BETTER) examining XB2001 (anti-IL-1? True Humanantibody) in combination with ONIVYDE + 5-FU/LV(+folinic acid) in advanced pancreatic cancer

Indication: Pancreatic Cancer

Location: Texas Oncology-Arlington Cancer Center North

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase I

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1b TRK-950 Ovarian Peri & Fallopian View

Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 XMT-1536 in Combo HGSOC (UPGRADE-A) View

Description: STUDY MER-XMT-1536-2A: UPIFITAMAB RILSODOTIN (XMT-1536) AN OPEN-LABEL MULTICENTER DOSE ESCALATION AND EXPANSION STUDY OF UPIFITAMAB RILSODOTIN IN COMBINATION WITH CARBOPLATIN IN PARTICIPANTS WITH HIGH-GRADE SEROUS OVARIAN CANCER(UPGRADE-A)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington South

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: I

Title: Ph1b TRK-950 Ovarian Peri & Fallopian View

Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 XMT-1536 in Combo HGSOC (UPGRADE-A) View

Description: STUDY MER-XMT-1536-2A: UPIFITAMAB RILSODOTIN (XMT-1536) AN OPEN-LABEL MULTICENTER DOSE ESCALATION AND EXPANSION STUDY OF UPIFITAMAB RILSODOTIN IN COMBINATION WITH CARBOPLATIN IN PARTICIPANTS WITH HIGH-GRADE SEROUS OVARIAN CANCER(UPGRADE-A)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1b TRK-950 Ovarian Peri & Fallopian View

Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 XMT-1536 in Combo HGSOC (UPGRADE-A) View

Description: STUDY MER-XMT-1536-2A: UPIFITAMAB RILSODOTIN (XMT-1536) AN OPEN-LABEL MULTICENTER DOSE ESCALATION AND EXPANSION STUDY OF UPIFITAMAB RILSODOTIN IN COMBINATION WITH CARBOPLATIN IN PARTICIPANTS WITH HIGH-GRADE SEROUS OVARIAN CANCER(UPGRADE-A)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 INCB123667 Mono Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Phase I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Phase II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Bedford

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Grapevine

Phase: II

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: PH2 MORab-202 NSCLC View

Description: A Phase 2 Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin) a Folate Receptor Alpha-targeting Antibody-Drug Conjugate in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: PH2 MORab-202 NSCLC View

Description: A Phase 2 Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin) a Folate Receptor Alpha-targeting Antibody-Drug Conjugate in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: PH2 MORab-202 NSCLC View

Description: A Phase 2 Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin) a Folate Receptor Alpha-targeting Antibody-Drug Conjugate in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: PH2 MORab-202 NSCLC View

Description: A Phase 2 Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin) a Folate Receptor Alpha-targeting Antibody-Drug Conjugate in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph1b/2 XMT-1536 ST NaPi2b View

Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph1b/2 XMT-1536 ST NaPi2b View

Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Phase II/III

Title: Ph II/III Raptor trial View

Description: Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial (NRG-LU007)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II/III

Phase III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant InvestigatorÂ's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 DAto-DXd PD1/PD L1 BC (TROPION Breast02) View

Description: D926PC00001: A Phase III Open-label Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02).

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 EpiOvarian FallTube PriPeritoneal View

Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 EpiOvarian FallTube PriPeritoneal View

Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: PH3 R-CHOP +/- Acalab Tx Naive DLBCL View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects < or = 70 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma (ACE-LY-312/ D8227C00001)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 EpiOvarian FallTube PriPeritoneal View

Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 EpiOvarian FallTube PriPeritoneal View

Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Upif Rilso Ovarian Cancer View

Description: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent Platinum-Sensitive Ovarian Cancer (UP-NEXT) (MER-XMT-1536-3 GOG-3049)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 EpiOvarian FallTube PriPeritoneal View

Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 EpiOvarian FallTube PriPeritoneal View

Description: (ALKS 4230-007/GOG-3063) A Phase 3 Multicenter Open-Label Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer (ARTISTRY-7)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nab-Pacli Ovarian Peritoneal Fallopian Cancer (ROSELLA) View

Description: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA) (CORT125134-556)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III